INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS (ARBs) AMONG SUDANESE PATIENTS

Azza A. Abdelazeim1, Asma N. Mahmoud Mohamed2, Mahmoud M. E. Mudawi3,4

1Delta Medical Establishment, UAE
2Faculty of Pharmacy, International University of Africa, Sudan
3Department of Pharmacology and Toxicology, Faculty of Pharmacy, Northern Border University, KSA
4Department of Pharmacology and Toxicology, Faculty of Pharmacy, Omdurman Islamic University, Sudan

ABSTRACT

Introduction: Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are widely used in the treatment of hypertension, left ventricular dysfunction, and diabetic nephropathy. Adverse effects of angiotensin II inhibitors include dry cough, dizziness, deterioration in renal function, hypotension, and Angioedema. Aim: This study aimed to evaluate the incidence of adverse drug reactions (ADR) of ACE inhibitors and angiotensin II receptor blockers among Sudanese patients. Methodology: This was a cross sectional study conducted in different hospitals and healthcare centers in Khartoum state, Sudan. A total of 120 patients were enrolled in this study. The data was collected using questionnaire. Results: This study revealed that most of the patients (37.5%) are using these drugs for less than one year, while 35% of the patients used these drugs for 2–5 years and lisinopril was the most drug prescribed (78.3%) for the patients. About 75% of the females did not receive advice regarding the use of these drugs during pregnancy. This study also showed that 46.7% of patients developed first-dose hypotension and 36.7% of the patients suffered from dry cough. Conclusion: Since 90.8% of the patients were not aware about the adverse drug reactions of their medications it is recommended to increase the awareness of the patients about the side effects of ACE inhibitors and ARBs.

INTRODUCTION

The renin system is an important mediator of blood volume, arterial pressure, cardiac and vascular function. Components of this system can be identified in many tissues, but the primary site of renin release is the kidney. The renin system can be triggered by sympathetic stimulation, renal artery hypotension, and decreased sodium delivery to distal tubule. The system is activated when there is a loss of blood volume or a drop in blood pressure.

Renin acts on oligopeptide substrate angiotensinogen to produce the decapeptide angiotensin I. In turn, angiotensin I is converted by angiotensin converting enzyme (ACE) to form octapeptide angiotensin II. Angiotensin II acts directly on the resistance vessels to increase systemic vascular resistance and arterial pressure, stimulate the adrenal cortex to release aldosterone, which lead to increased cardiac and vascular hypertrophy. The peptide angiotensin II (ANG II) plays an important role in cardiac and vascular disorder.

*Corresponding author: Azza A. Abdelazeim
Delta Medical Establishment, UAE

Both angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are widely used in renal failure patients, in the treatment of hypertension, left ventricular dysfunction, and diabetic nephropathy. Their efficacy in these conditions is well established, and generally both classes of drugs are well tolerated, with a low incidence of site effect.

Adverse effects of angiotensin II inhibitors include cough, dizziness, and deterioration in renal function, although the overall incidence of hypotension and renal impairment in the consensus and solved studies was only 5%. Angioedema related to ACEIs is rare, although more common in patients of Afro-Caribbean origin than in other ethnic groups.

Renin angiotensin inhibitors also demonstrate a less favorable response when used alone in black patient, although this is eliminated by addition of other drug. This reduce efficacy results from the low renin salt-sensitive profile and is particular propel in the elderly black patient. Therapies aimed at modifying the renin system have been used extensively for treatment of hypertension, heart failure, myocardial infraction, and diabetes, and renal disease.
ACE inhibitors can be subdivided into 3 classes with regard to the active group: the majority of ACE inhibitors are carboxyl-containing drugs (like lisinopril), a new class of ACE inhibitors possess a phosphoryl --group (like fosinopril) and sulfhydryl-containing drugs (like Captopril) (11).

ACEIs block conversion of angiotensin I to angiotensin II. Thus they inhibit angiotensin II release and bradykinin inactivation (12).

Most ACE inhibitors are prodrugs which are converted by hepatic esterolysis to an active metabolite. The predominant elimination pathway of ACE inhibitors is excretion via the kidneys and for most ACE inhibitors, dosage adjustment is recommended in moderate and severe impairment of renal function (13). The bioavailability among ACE inhibitors varies widely (14).

On the other hand, angiotensin receptor blockers (also known as ARBs) are non-peptide compounds with varied structure (15). ARBs selectively inhibit angiotensin II from activating the angiotensin-specific receptor (AT1) and they have no effect on bradykinin metabolism and therefore more selective blockers of angiotensin effect than ACEIs (16). After oral administration, the ARBs are rapidly absorbed but they have a wide range of bioavailability (15).

Angiotensin-converting enzyme (ACE) inhibitors have produced functional and clinical outcome benefits in clinical trials of patients with congestive heart failure, systolic dysfunction after myocardial infarction, and diabetic nephropathy. Similar favorable trends have been noted in observational studies in hypertension (17)(18).

Black patients may be less sensitive than white patients to ACE inhibitors as monotherapy for hypertension, although ACE inhibitors are relatively ineffective as monotherapy in blacks (19)(20)(21).

Guidelines issued in 2009 by the European Society of Hypertension, and in 2011 by NICE (National Institute for Health and Clinical Excellence of Great Britain), recommend the use of an ACE inhibitor or angiotensin II receptor blocker (ARB) in younger and non-black patients (22).

It is reported that the combination of maximum doses of Aliskiren (direct renin inhibitor) and valsartan decreased blood pressure more than maximum doses of either agent alone but not more than would be expected with dual (23).

In patients with type I diabetes, blocking the RAS with angiotensin converting enzyme (ACE) inhibitors prevents progression from micro albuminuria to overt nephropathy, and in overt nephropathy decreases the gradual loss of renal function beyond its blood pressure lowering effect (24)(25).

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers are contraindicated in patients with bilateral renal artery stenosis due to risk of azotemia resulting from preferential efferent arteriolar vasodilator, vasodilation in the renal glomerulus due to inhibition of angiotensin II (26).

Therapy with ACEIs and ARBs is contraindicated in patients with a prior history of idiopathic Angioedema (27). Both ACE inhibitor and angiotensin receptor antagonist are contraindicated during pregnancy (28).

Angiotensin converting enzyme (ACE) inhibitors are useful first line drug in the therapy of mild and moderate hypertension. Adverse reactions to this drugs class are rarely serious. Hypotension, cough, rash, and taste disturbance are uncommon. Reduced glomerular filtration and hyperkalemia occur infrequently angioedema is rare and neutropenia is extremely rare (29).

In general, the ARBs are well tolerated. None of the drugs reviewed has a specific, dose-dependent adverse effect. The frequency of cough has been significantly lower in patients taking ARBs than in patients taking Lisinopril (30).

A well-documented side effect of ACEIs is a persistent dry cough, the frequency of which ranges from 5–20%. The side-effect usually develops within a few weeks after ACEIs initiation; is not dose-dependent and is more common in women. The persistent and troublesome nature of the cough often warrants discontinuation of the ACEIs, after which the side effect will usually abate within a few days. Substitution of the ACEIs with alternative agents, preferably angiotensin II antagonists, is recommended (31)(32).

ACE inhibitor-related angioedema is more common than was first imagined with the risk being as high as 5.54% in blacks. ACE inhibitor treated patients who have experienced an episode of angioedema can have a similar occurrence with angiotensin receptor blocker (ARB) therapy, albeit much less frequently. Angioedema, although life threatening, seldom proves fatal. (33).

First dose hypotension has been recognized as a potential limiting factor in the use of ACE inhibitors in the treatment of chronic heart failure. Concerns regarding first-dose hypotension may increase the risk of renal, myocardial, or cerebral hypoperfusion. The incidence of first-dose hypotension after ACE inhibitors reported in large clinical trials is small, varying from 0.7% in the SAVE trial to 9.4% in the CCS-I trial (34).

Hyperkalemia has been attributed to the use of ACE inhibitors in 10 to 38 percent of hospitalized patients with this complication. Hyperkalemia develops in approximately 10 percent of outpatients within a year after these drugs are prescribed. Patients at greatest risk for hyperkalemia include those with diabetes and those with impaired renal function in whom a defect in the excretion of renal potassium may already exist (35).

Justification

Renin angiotensin aldosterone system inhibitor drugs such as ACEIs and ARBs are very useful in treatment of different diseases situation. However, most of the studies has been carried in countries other than Sudan. Taking in mind that there might be different factors such as genetic and diet among Sudanese which may affect their adverse drug reactions. Therefore, the aim of this study is to evaluate the safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers drugs in Sudanese patients.

METHODOLOGY

This was cross sectional study conducted in different hospitals and healthcare centers in Khartoum state, Sudan. It included Patients who are taking angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). A
total of 120 patients were enrolled in this study during May to September (2012), the data was collected using questionnaire.

Ethical consideration

This study was approved by the research committee of the faculty of pharmacy International University of Africa and also by the research committee, ministry of health Khartoum state, Sudan.

RESULTS

Table 1: Shows the distribution of gender in this study

| Gender | Frequency | Percentage (%) |
|--------|-----------|----------------|
| Male   | 63        | 52.5           |
| Female | 57        | 47.5           |
| Total  | 120       | 100.0          |

Figure 1: Gender distribution
As shown in table (1) and figure (1), 52.5 % of the participants were males and 47.5 % were females.

Table 2: Shows the duration of treatment

| Duration of treatment | Frequency | Percentage (%) |
|-----------------------|-----------|----------------|
| less than one year    | 45        | 37.5           |
| Year                  | 12        | 10.0           |
| 2-5 years             | 42        | 35.0           |
| 5-10 years            | 15        | 12.5           |
| >10 years             | 6         | 5.0            |
| Total                 | 120       | 100.0          |

Figure 2: Shows the duration of treatment.
As shown in table (2) and figure (2) most of the patients (37.5 %) used the drugs for less than one year, while 35 % of the patients used the drugs for 2 – 5 years.

Table 3: Describe the Distribution of drugs used by the patients:

| Drug       | Frequency | Percentage (%) |
|------------|-----------|----------------|
| Candesartan| 5         | 4.2            |
| Captopril  | 2         | 1.7            |
| Lisinopril | 94        | 78.3           |
| Losartan   | 17        | 14.2           |
| Ramipril   | 1         | 0.8            |
| Valsartan  | 1         | 0.8            |
| Total      | 120       | 100.0          |

Figure 3: indicates the commonly used drugs.
It is found that Lisinopril was the most drug prescribed (78.3%) for the patients (table 3 and figure 3).

Table 4: Indicates the percentage of females who were advised to stop using drug during pregnancy and lactation period:

| Frequency | Percentage (%) |
|-----------|----------------|
| Yes       | 14             |
| No        | 42             |
| Total     | 56             |

Figure 4: describe the percentage of females who were advised to stop using the drugs.
This study revealed that 75 % of the females did not receive advice stop using these drugs during pregnancy and lactation period (table 4 and figure 4).

Table 5: shows the percentage of the patients who were aware about the adverse drug reactions of their medications:

| Frequency | Percentage (%) |
|-----------|----------------|
| Yes       | 11             |
| No        | 109            |
| Total     | 120            |

Figure 5: shows the awareness about adverse drug reactions. It is found that 90.8% of the patients are not aware about the adverse drug reactions of their medications (table 5 and figure 5).

Table 6: Frequency of Patient suffered from hypotension

| First dose hypotension | frequency | Percentage (%) |
|------------------------|-----------|----------------|
| Yes                    | 56        | 46.7           |
| No                     | 64        | 53.3           |
| Total                  | 120       | 100            |

Figure 6: Indicates the frequency of the patients suffered from hypotension.
In this study 46.7 % of the patients suffered from hypotension (table 6 and figure 6).

Table 7: Frequency of patients suffered from cough

| Frequency | Percentage (%) |
|-----------|----------------|
| Yes       | 44             |
| No        | 75             |
| Total     | 119            |

Figure 7: Describe the percentage of the patients suffered from cough
As in table (7) and figure (7), 36.7% of the patients suffered from dry cough.

Table 8: Number of patients who measured serum potassium level

| Measured serum potassium level | Frequency | Percentage (%) |
|-------------------------------|-----------|----------------|
| Yes                           | 23        | 19.2           |
| No                            | 97        | 80.8           |
| Total                         | 120       | 100            |

Figure 8: Shows the number of patients who measured serum potassium level.
Table (8) and figure (8) shows that 80.8 % of patient did not measure their serum potassium level.

Table 9: Number of patients with hyperkalemia

| Serum potassium level | Frequency | Percentage (%) |
|----------------------|-----------|----------------|
| Hyperkalemia         | 9         | 39.1           |
| Normal               | 14        | 60.9           |
| Total                | 23        | 100            |

Figure 9: Indicates the number of patients developed hyperkalemia.
This study indicated that 39.1% of the patients who measured their serum potassium level suffered from hyperkalemia (table 9 & figure 9).

DISCUSSION

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are widely used in the treatment of hypertension, left ventricular dysfunction, and diabetic nephropathy. Adverse effects of angiotensin II inhibitors include cough, dizziness, and deterioration in renal function. Angioedema related to ACEIs is rare, although more common in patients of Afro-Caribbean origin than in other ethnic group.
enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in Sudanese patients.

In this study 52.5% of the study population were male and 47.5% were female. The duration of the treatment for the majority of the patients (37.5 %) is less than one year.

Generally, different drugs of ACEIs and ARBs are regularly used among the population, but the most common drug is Lisinopril (78.3 %), factors considered may be due to it is wide distribution, availability and affordable cost.

This study showed poor awareness about the use of renin system inhibitors during pregnancy about 75 % of the females in this study indicated that they did not receive advise to stop using these drugs during pregnancy and lactation. Myla et al. (2012) stated that ACEIs and ARBs, are strictly prohibited in pregnancy due to their undesirable effects on the fetus (26).

As indicated this study focused on the side effects of ACEIs and ARBs. 90.8 % of the patients included in this study were not aware about the adverse drug reactions of renin system inhibitors.

This research revealed that 46.7% of patients suffered from first dose hypotension. This percentage is considered high compared to other studies which reported that the incidence of first-dose hypotension after ACE inhibitors reported in large clinical trials is small, varying from 0.7% in the SAVE trial to 36.7 % of the patients in this study indicated that they did not receive advise to stop using these drugs during pregnancy and lactation. Myla et al. (2012) stated that ACEIs and ARBs, are strictly prohibited in pregnancy due to their undesirable effects on the fetus (26).

80.8% of the patients were not asked to measure their serum potassium level.

This study showed that 39.1 % of the patients who measured serum potassium level developed hyperkalemia. It is reported that the frequency of dry cough ranges from 5–20% and usually develops within a few weeks after ACEIs initiation; it is not dose-dependent and is more common in women. The persistent and troublesome nature of the cough often warrants discontinuation of the ACEIs, after which the side effect will usually abate within a few days (31)-(32).

CONCLUSION

This study showed poor awareness about the use of renin system inhibitors during pregnancy and the incidence of first dose hypotension and dry cough is high. Therefore, awareness about the use, side effects and drug-drug interactions of Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers should be improved.

Acknowledgement

This work was supported by the faculty of Pharmacy, International University of Africa, Sudan.

References

Iain C. Macdougall, The role of ACE inhibitors and angiotensin II receptor blockers in the response to epeoin, Nephrol Dial Transplant (1999) volume14, no (8): page 1836-1841. DOI:https://doi.org/10.1093/ndt/14.8.1836

Matthew R. Weir, Victor J. Dzau, The renin-angiotensin-aldosterone system: a specific target for hypertension management, Am J Hypertens (1999) volume 12 no (S9): page 205S-213S. DOI:https://doi.org/10.1016/S0895-7061(99)00103-X

Karl T. Weber, M.D Mechanisms of Disease Aldosterone in Congestive Heart Failure, N Engl J Med, 2001; 345:1689-1697 DOI: 10.1056/NEJMra000050

Maricica Pucarari,1,2 Ramzi Kafoury,1,2 Paul B. Tchounwou,1,2 and Kenneth Ndebele1,2 The Renin-Angiotensin-Aldosterone System in Vascular Inflammation and Remodeling, Volume 2014 (2014), Article ID 689360, 13 pages DOI: http://dx.doi.org/10.1155/2014/689360

Steven A .ATLAS, The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition, J Manage Care Pharm. 2007 Oct; volume 13 issue no (8 Supp B) page: 9-20. DOI: http://dx.doi.org/10.18553/jmcp.2007.13.s8-b.9

Izzo JL Jr1, Weir MR, Angiotensin-converting enzyme inhibitors, J Clin Hypertens (Greenwich), 2011 Sep; volume 13, no (9):page 667-75. DOI:10.1111/j.1751-7176.2011.00508. X.

M K Davies, C R Gibbs, and G Y H Lip, ABC of heart failure Management: diuretics, ACE inhibitors, and nitrates, BMJ. 2000 Feb 12; 320(7232): 428-431, PMC1117548.

C.R. Gibbs, D.G. Beevers, G.Y.H. Lip, The management of hypertensive disease in Black patients, oxford journal medicin, 1 April 1999 volume 92 issue no 4 page no 187-192 DOI:https://doi.org/10.1093/qjmed/92.4.187

Sandra F Williams, Susanne B Nicholas, Nosratola D Vaziri, and Keith C Norris, African Americans hypertension and the renin angiotensin system, World J Cardiol. 2014 Sep; volume 26; issue no 6(9): page 878-889. Doi: 10.4330/wjc.v6.i9.878

Terry KW Ma, Kevin KH Kam, Bryan P Yan, and Yat-Yin Lam, Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status, Br J Pharmacol. 2010 Jul; volume160 issue no (6): page1273-1292. Doi: 10.1111/j.1476-5381.2010.00750.x

Hoyer J1, Schulte KL, Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokinet. 1993 Mar; volume24, issue no (3):page230-54. DOI:10.2165/00002088-199324030-00005

Tatjana Ignjatovic, Fulong Tan, Viktor Brovkovych, Randal A. Skidgel and Ervin G. Erdös‡ Novel mode of action of angiotensin I converting enzyme inhibitors: 2002 May direct activation of bradykinin B1 receptor. J Biol Chem. 2002 May volume 10; issue no 277(19):16847-52.

RW Piepho, Overview of the angiotensin-converting enzyme inhibitors. American Journal of Health-System
Assessment Of Adverse Drug Reactions Of Angiotensin Converting Enzyme (Ace) Inhibitors And Angiotensin Receptor Blockers (Arbs) Among Sudanese Patients

Pharmacy October 1, 2000 vol. 57 no. suppl 1 S3-S7 PMID:11030016

Fischler MP1, Fallth F. [Comparative evaluation of ACE inhibitors: which differences are relevant?]. Schweiz Med Wochenschr. 1999 Jul vol 27; issue no129 (29-30): page 1053-60 PMID: 10464907

ZH Israili, clinical pharmacokintik of angiotensin 11 (AT1) receptor blockers in hypertension, journal of human hypertension (2000) volume 14, suppl 1, s 73-s86 PMID: 10854085

Georg Nickenig,* Jan Östergren, Harry Struijker-Boudier†, Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers, J Renin Angiotensin Aldosterone Syst 2006 7: S1. DOI: 10.3317/jraas.2006.017

J M Ritter, Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension, BMJ 2011; 342 PMID: 10854085

Weber MA1. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens. 1999 Dec; volume 12, issue (12 Pt 3):189S-194S. DOI: https://doi.org/10.1016/S0895-7061(99)00105-3

A A Lopes, March 2002, Hypertension in black people: pathophysiology and therapeutic aspects, journal of human hypertension, Volume 16, Supplement 1, Pages S11-S12. DOI: 10.1038/sj/jhh/1001333

Neil B. Shulman, Treatment of Hypertension in Black Patients with Angiotensin-Converting Enzyme Inhibitors, J Natl Med Assoc. 1988 Mar; 80(3): 265–272.PMC2625639

Lindhorst JL, Alexander N, Blignaut J, Rayner B. Differences in hypertension between blacks and whites: an overview, Cardiovasc J Afr. 2007 Jul-Aug;volume,18issue no(4):241-7. PMID: PMC4170224

Giuseppe Mancia, Ste´phane Laurentb, Enrico Agabiti-Roseic, Ettore Ambrosionid, Michel Burniere, Mark J. Caulfieldf, Renata Cifkog, Denis Cle’menth, Antonio Cocai, Anna Dominiczakj, Serap Erdineke, Robert Fagardl, Csaba Farsangm, Guido Grassin, Hermann Hallero, Antony Heagertyp, Sverre E. Kjeldsenq, Wolfgang Kiowski, Jean Michel Mallions, Athanasios Manolist, Krzysztof Narkiewicz, Peter Nilssonov, Michael H. Olsenw, Karl Heinz Rahnx, Josep Redony, Jose’ Rodicio, Luis Rulopea1, Roland E. Schmieder2, Harry A. J. Struijker-Boudier3, Pieter A. van Zwietaen4, Margus Virgimaana5 and Alberto Zanchetta. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121.

Pramay Wal, Ankita Wal, Awani K. Rai, and Anuj Dixit, Aliskiren: An orally active renin inhibitor, J Pharm Bioallied Sci. 2011 Apr-Jun; 3(2): 189-193. DOI: 10.4103/0975-7406.80764

Amanda N. Long, DO and Samuel Dagogo-Jack, MD, The Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection, J Clin Hypertens (Greenwich). 2011 Apr; volume 13, issue no (4): page 244-251. DOI: 10.1111/j.1751-7176.2011.00434.x

J Karahiedde and G Viberti, Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes, Journal of Human Hypertension (2006) volume 20, page 239-253. DOI:10.1038/sj.jhh.1001982; published online 2 February 2006

Khosla S1, Ahmed A, Siddiqui M, Trivedi A, Benatar D, Salem Y, Elzbour M, Vidarthi V, Lubell D, Safety of angiotensin-converting enzyme inhibitors in patients with bilateral renal artery stenosis following successful renal artery stent revascularization, Am J Ther. 2006 Jul-Aug; volume 13issue no (4):306-8. PMID: 16858164

Sabroe RA1, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema, Br J Dermatol. 1997 Feb; volume 136 issue no (2):153-8. PMID: 9068723

Myla E. Moretti, Daniela Caprara, Irina Drehuta, Emily Yeung, Stefanie Cheung, Luisa Federico, and Gideon Koren, The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers, Obstetrics and Gynecology International, Volume 2012 (2012), Article ID 658310, 6 pages DOI: http://dx.doi.org/10.1155/2012/658310

Materson BJ, Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril, Am J Cardiol. 1992 Apr 2; 69(10):46C-53C PMID: 1546639

M Volpe, L M Rulope G T McInnes, B Waebber and M A Weber, Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? Journal of Human Hypertension (2005) 19, 331-339. Published online 3 March 2005

Stefan Vegter and Lolijke T W de Jong-van den Berg, Misdagnosis and mistreatment of a common side-effect – angiotensin-converting enzyme inhibitor-induced cough, Br J Clin Pharmacol. 2010 Feb; volume 69 issue (2): 200-203. DOI: 10.1111/j.1365-2125.2009.03571.x

F J Mackay, G L Pearce, and R D Mann, Cough and angiotensin II receptor antagonists: cause or confounding?, Br J Clin Pharmacol. 1999 Jan; volume 47 issue no (1): 111-114. Doi: 10.1046/j.1365-2125.1999.00855.x

Domenic A. Sica MD and Henry R. Black MD 2, ACE Inhibitor-Related Angioedema: Can Angiotensin-Receptor Blockers Be Safely Used? The Journal of Clinical Hypertension, Volume 4, Issue 5, pages 375–380, September/October 2002 DOI: 10.1111/j.1524-6175.2002.01509.x

Vitovec Jir†, Špinar Jindrich and Czech and Slovak Investigator Group, First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril, European Journal of Heart Failure, Volume 2, Issue 3, pages 299-304, September 2000 DOI: 10.1016/S1388-9842(00)00095-7

Biff F. Palmer, M.D, Managing Hyperkalemia Caused by Inhibitors of the Renin–Angiotensin–Aldosterone System, N Engl J Med 2004; 351:585-592August 5, 2004 DOI: 10.1056/NEJMra035279